The issue is the 4th quarter. They kind of crapped the bed. Cost of revenue tripled, I could understand it doubling because costs doubled, but tripled? Hard pill to swallow. Still undervalued here should be at .025. I'm looking at a strong 1q 2022. $$$JNSH$$$